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The dendritic cell-specific C-type lectin DC-SIGN
functions as a pathogen receptor that recognizes Schis-
tosoma mansoni egg antigens through its major glycan
epitope Gal1,4(Fuc1,3)GlcNAc (Lex). Here we report
that L-SIGN, a highly related homologue of DC-SIGN
found on liver sinusoidal endothelial cells, binds to S.
mansoni egg antigens but not to the Lex epitope. L-SIGN
does bind the Lewis antigens Lea, Leb, and Ley, similar
as DC-SIGN. A specific mutation in the carbohydrate
recognition domain of DC-SIGN (V351G) abrogates bind-
ing to all Lewis antigens. In L-SIGN Ser363 is present at
the corresponding position of Val351 in DC-SIGN. Re-
placement of this Ser into Val resulted in a “gain of
function” L-SIGN mutant that binds to Lex, and shows
increased binding to the other Lewis antigens. These
data indicate that Val351 is important for the fucose
specificity of DC-SIGN. Molecular modeling and docking
of the different Lewis antigens in the carbohydrate rec-
ognition domains of L-SIGN, DC-SIGN, and their mutant
forms, demonstrate that Val351 in DC-SIGN creates a
hydrophobic pocket that strongly interacts with the
Fuc1,3/4-GlcNAc moiety of the Lewis antigens. The
equivalent amino acid residue Ser363 in L-SIGN creates
a hydrophilic pocket that prevents interaction with
Fuc1,3-GlcNAc in Lex but supports interactions with
the Fuc1,4-GlcNAc moiety in Lea and Leb antigens.
These data demonstrate for the first time that DC-SIGN
and L-SIGN differ in their carbohydrate binding profiles
and will contribute to our understanding of the func-
tional roles of these C-type lectin receptors, both in rec-
ognition of pathogen and self-glycan antigens.
Dendritic cell-specific intercellular adhesion molecule-3
(ICAM-3)1-grabbing nonintegrin (DC-SIGN, CD209) is a type II
membrane C-type lectin with a short amino-terminal cytoplas-
mic tail and a single carboxyl-terminal carbohydrate recogni-
tion domain (CRD). DC-SIGN is a cell adhesion receptor that
mediates interactions between dendritic cells (DCs) and resting
T cells through binding to ICAM-3 and supports trans-endo-
thelial migration through interaction with ICAM-2 (1, 2). DC-
SIGN has also been described as a pathogen receptor. It binds
human immunodeficiency virus type 1 (HIV-1) gp120 and fa-
cilitates the transport of HIV from mucosal sites to draining
lymph nodes where infection of T-lymphocytes occurs (3). Re-
cent reports show that DC-SIGN binds to other viruses like
hepatitis C (4, 5), Ebola (6), cytomegalovirus (7), and Dengue
(8), as well as other pathogens such as Mycobacterium (9–11),
Leishmania (12, 13), and Candida albicans (14). Recently we
showed that DC-SIGN binds soluble egg antigens (SEA) of the
helminth parasite Schistosoma mansoni through the Lewis x
(Lex, CD15) glycan antigen (15). This binding to Lex and SEA
was abrogated by mutation of the Val at position 351 in the
CRD of DC-SIGN.
Liver/lymph node-specific ICAM-3-grabbing nonintegrin (L-
SIGN/CD209L/DC-SIGN-R) is a human homologue of DC-
SIGN. L-SIGN shares 77% amino acid sequence identity with
DC-SIGN and has functional similarity by recognizing ICAM-2,
ICAM-3, and HIV-1 gp120. In addition, elucidation of the crys-
tal structures of the CRDs of both DC-SIGN and L-SIGN, in
combination with binding studies, revealed that both receptors
recognize high mannose oligosaccharides (16, 17). Whereas for
DC-SIGN increasing evidence indicates that its major ligands
are 3/4-fucosylated glycans (15, 18, 19), no data so far indi-
cate a role for L-SIGN in the binding of fucosylated oligosac-
charides. L-SIGN is not expressed by DCs but is expressed by
endothelial cells present in lymph node sinuses, capillary en-
dothelial cells of the placenta, and liver sinusoidal endothelial
cells (20–23). Because liver sinusoidal endothelial cells func-
tion as a liver-resident antigen presenting cell population (24),
it is of particular interest to investigate whether L-SIGN plays
a role in the recognition and uptake of glycosylated schistosome
egg antigens that are secreted by eggs trapped in the liver of
schistosome-infected hosts.
Here we demonstrate that L-SIGN interacts with S. mansoni
SEA but recognizes another glycoprotein fraction than DC-
SIGN does, suggesting that L-SIGN does not recognize Lex.
Indeed, binding assays with L-SIGN demonstrated a lack of
binding of L-SIGN to neoglycoconjugates carrying Lex but
showed that L-SIGN recognizes other fucosylated glycans, i.e.
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Lewis a (Lea), Lewis b (Leb), and Lewis y (Ley). Site-specific
mutagenesis of the amino acid residue Ser363 in L-SIGN into a
Val, as is present in DC-SIGN at this position, resulted in a
“gain of function” mutant that binds to neoglycoconjugates
carrying Lex and shows increased binding to the other Lewis
antigens. Molecular modeling of the CRDs of the wild-type and
mutant lectins demonstrated that Val351 in DC-SIGN, which is
lacking in L-SIGN, may be critically involved in the binding to
Lex and Lea by creating a strong hydrophobic contact with the
fucose. These data show for the first time that DC-SIGN and
L-SIGN differ in their carbohydrate recognition profiles and
propose a molecular model that explains the observed differen-
tial binding of these lectins to fucosylated glycan antigens.
EXPERIMENTAL PROCEDURES
Antibodies and Neoglycoconjugates—The following antibodies were
used, AZN-D1 (IgG1, anti-DC-SIGN), AZN-D2 (anti-DC-SIGN/anti-L-
SIGN) (1, 22), and anti-LDN monoclonal antibody SMLDN1.1 (25).
Crude S. mansoni SEA extract was centrifuged for 90 min at 100,000 
g at 4 °C and sterilized by passing through a 0.2 M filter, essentially as
described by Nyame et al. (26). Neoglycoconjugates, containing glycans
multivalently coupled to biotinylated polyacrylamide (PAA) were from
Lectinity (Finland).
Mutagenesis—Mutations in the cDNA encoding L-SIGN were gener-
ated using the QuikChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA) and pRc/CMV-L-SIGN plasmid according to the manufac-
turer’s protocol. Plasmid sequencing confirmed the introduction of a
mutation in the Ser residue at position 363 into Val (S363V) or Gly
(S363G). Stable K562 cell lines expressing L-SIGN mutants were gen-
erated by the transfection of K562 cells with 10 g of plasmid as
described previously (3, 27, 28). Positive cells were sorted several times
with the antibody AZN-D2 to obtain stable transfectants with similar
expression levels (see Fig. 3B, 85%).
Binding Assay—Stable K562 cells expressing different wild-type and
mutant C-type lectins (5  104 cells) were incubated in a total volume
of 25 l with biotinylated PAA-linked glycoconjugates (5 g/ml) in
adhesion buffer (20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM CaCl2,
2 mM MgCl2, and 0.5% bovine serum albumin) for 30 min at 37 °C. Cells
were washed with adhesion buffer and incubated with streptavidin-
Alexa Fluor 488 secondary antibody (Molecular Probes, Inc., Eugene,
OR) for 20 min at room temperature and analyzed using flow cytometry
in the FL-1 channel (FACScan, BD Biosciences).
Fluorescent Bead Adhesion Assay—For measuring SEA binding to
whole cells, a bead adhesion assay was used as described previously (27).
Streptavidin was covalently coupled to TransFluorSpheres, fluorescent
beads with a size of 1.0 m and fluorescence at 488/654 nm (Molecular
Probes Inc.). The streptavidin-coated beads were incubated with a bioti-
nylated F(ab)2 fragment of goat anti-mouse IgG (6 g/ml, Jackson Im-
munoResearch) followed by an overnight incubation at 4 °C with anti-
LDN monoclonal antibody. The beads were washed and incubated with 1
g/ml SEA overnight at 4 °C (15). Alternatively, SEA was biotinylated
with EZ-linkTM NHS-LC-LC-biotin, according to the manufacturer’s pro-
tocol (Pierce). Biotinylated SEA (SEA-bio) was directly coupled to the
streptavidin-coated fluorescent beads. HIV gp120 fluorescent beads were
prepared as described previously (3). Briefly, for the fluorescent beads
adhesion assay 50 103 cells were resuspended in adhesion buffer (20 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2, and 0.5%
bovine serum albumin). Ligand-coated fluorescent beads (20 beads/cell)
were added to the cells, and the suspension was incubated for 45 min at
37 °C. Cells were washed, and adhesion was determined using flow cy-
tometry (FACScan) by measuring the percentage of cells that had bound
fluorescent beads in the FL-3 channel.
Molecular Modeling—The starting coordinates of human DC-SIGN
and L-SIGN (17) were taken from the Protein Data Bank (29) using files
with code 1K9I and 1K9J, respectively. Using the Sybyl software (Tri-
pos Inc., St. Louis, MO), the structures were edited to contain only one
protein monomer together with calcium ions. Protein hydrogen atoms
were added, the peptide atoms partial charges were calculated using
the Pullman procedure, and the calcium ions were given a charge of 2.
The positions of the hydrogen atoms were refined with the use of the
Tripos force field (30). Lewis oligosaccharides were built from a data
base of three-dimensional structures of monosaccharides with their
glycosidic torsion angles corresponding to the lowest energy conforma-
tion determined previously (31). Atom types and charges for oligosac-
charides were defined using parameters developed for carbohydrates
(32).
Docking of oligosaccharides in the binding sites was performed by
testing the several possible orientations of the fucose hydroxyl groups in
the coordination sphere of the calcium ion. Energy minimization was
performed using the Tripos force field (30) with geometry optimization
of the sugar and the side chains of amino acids in the binding sites. A
distance-dependent dielectric constant was used in the calculations.
Energy minimizations were carried out using the Powell procedure
until a gradient deviation of 0.05 kcalmol1Å1 was attained.
RESULTS
L-SIGN Shows Binding to S. mansoni SEA—In a previous
study (15), we showed that DC-SIGN binds S. mansoni SEA
through the recognition of Lex antigens. To investigate the
binding properties of L-SIGN to SEA, we used a fluorescent
bead adhesion assay with K562 transfectants stably expressing
L-SIGN or DC-SIGN (Fig. 1A). Streptavidin-coated fluorescent
beads were precoated with monoclonal antibodies recognizing
LDN glycan antigens (25) that occur on a SEA glycoprotein
fraction that simultaneously carries Lex glycan antigens (15).
These LDN-coated fluorescent beads were then used to capture
SEA and incubated with K562 cells expressing L-SIGN as
described previously for DC-SIGN (15). The LDN-captured
SEA beads interacted with K562 cells expressing DC-SIGN;
however we could not observe any binding to L-SIGN (Fig. 1C).
However, by using this approach only a fraction of the SEA was
coated on the beads (i.e. only SEA containing LDN glycans also
carrying Lex (15)). To investigate binding of L-SIGN to the
whole SEA population, SEA was biotinylated and directly
coated on streptavidin-coated fluorescent beads. Interestingly,
K562 cells expressing L-SIGN bound to beads carrying bioti-
nylated SEA (Fig. 1, B and C). In agreement with previous
results L-SIGN was able to bind HIV-1 gp120 beads in a man-
ner similar to DC-SIGN (Fig. 1C) (22). The binding of beads
coated with biotinylated SEA to both DC-SIGN and L-SIGN
could be blocked by the anti-DC-SIGN/L-SIGN antibody
AZN-D2 and by EDTA, which removes the Ca2 ions that are
essential for carbohydrate binding, indicating that the CRDs of
the lectins are involved in the binding of SEA (Fig. 1D). These
data show that L-SIGN binds S. mansoni SEA but recognizes a
different subset of SEA compared with DC-SIGN, which sug-
gests that L-SIGN differs from DC-SIGN in its ability to bind
Lex glycan antigens.
L-SIGN Does Not Bind to Lex but Recognizes Other Lewis
Antigens—Because our previous data indicated that the trisac-
charide Lex on schistosome SEA is a ligand for DC-SIGN, we
next investigated whether L-SIGN binds to Lex glycans linked
to biotinylated PAA. The results in Fig. 2 show that K562 cells
expressing L-SIGN did not bind Lex-PAA in contrast to K562
cells expressing DC-SIGN that strongly bound to Lex-PAA. The
binding of DC-SIGN to Lex-PAA could be inhibited by a block-
ing antibody against DC-SIGN (AZN-D2) and by the calcium
chelator EGTA (Fig. 2B).
It has been described that the CRD of DC-SIGN binds two
Ca2 ions and that amino acids in close contact with these Ca2
binding sites are essential for ligand binding (1, 28). The amino
acid sequences of the CRD domains of L-SIGN and DC-SIGN
show a high identity (Fig. 3A). Recently we showed that muta-
tion of amino acid residue Val351 into a Gly in DC-SIGN (Fig.
3A, V351G) abrogated the binding to SEA and Lex, whereas
binding to HIV gp120 was not affected (15, 28). This suggests
that Val351 within the CRD of DC-SIGN is important for the
binding of DC-SIGN to Lex. In L-SIGN, a Ser is located at the
position of Val in DC-SIGN. To determine the molecular basis
for the difference in carbohydrate specificity between L-SIGN
and DC-SIGN, two mutations were made in the CRD domain of
L-SIGN in which Ser at position 363 is converted into a Val
(S363V) or alternatively into a Gly (S363G) (Fig. 3A). The
carbohydrate binding capacity of K562 cells expressing these
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L-SIGN mutant forms was compared with K562 cells express-
ing similar levels of wild-type L-SIGN, DC-SIGN, and the
DC-SIGN V351G mutant, respectively (Fig. 3B). Both wild-
type L-SIGN and DC-SIGN showed binding to biotinylated
neoglycoconjugates containing Lea, Leb, and Ley but not to
sialyl Lex (sLex) (Table I and Fig. 3C). EGTA and a blocking
anti-DC-SIGN/L-SIGN antibody could inhibit this binding
(data not shown). Remarkably, the L-SIGN mutant S363V
showed binding to Lex, in contrast to the wild-type L-SIGN
(Fig. 3C). The introduction of this Val residue also induced
increased binding of the L-SIGN S363V mutant to Lea, Leb, and
Ley (Fig. 3C), and to S. mansoni SEA (data not shown). The
conversion of Val351 into a Gly in DC-SIGN (DC-SIGN V351G)
abrogated binding to all Lewis antigens. Similarly, the L-SIGN
S363G mutant showed no binding to any of the Lewis antigens
tested (Fig. 3C). These results demonstrate that cell-surface-
expressed L-SIGN and DC-SIGN differ in their binding prop-
erties to Lex. Both lectins, however, show a functional similar-
ity in their capacity to bind to Lea, Leb, and Ley glycan
antigens, and their lack of binding to sLex. Our data indicate
that amino acid residue Val351 in DC-SIGN, which is lacking in
L-SIGN, is critically involved in the binding of DC-SIGN to Lex
glycan structures.
Docking of Lewis x in DC-SIGN—To gain more insight in the
molecular basis that determines the differences in binding
properties of DC-SIGN and L-SIGN to Lex, molecular modeling
studies were undertaken. Because DC-SIGN and L-SIGN have
been crystallized with mannose-containing oligosaccharides
(17), but not with fucose containing ones, the possible interac-
tions of Lex with the CRD of DC-SIGN was determined first.
Several binding modes of fucose, or fucose-containing oligosac-
charides, have been observed when comparing crystal struc-
FIG. 1. Fluorescent beads adhesion assays of S. mansoni SEA with K562 cells expressing L-SIGN or DC-SIGN. A, K562 cells stably
transfected with L-SIGN or DC-SIGN have similar expression levels as determined by FACScan analysis using monoclonal antibody AZN-D2 that
recognizes a common epitope on L-SIGN and DC-SIGN. B, SEA was biotinylated and coupled to streptavidin-coated fluorescent beads (SEA-bio).
Binding of the beads to the cells was measured by FACScan analysis using Cellquest (BD Biosciences). The dotplots (left panel) show the
forward-side scatter (FSC) of the cells in the presence of SEA-bio. The adhesion of the beads to the cells is measured in the FL-3 channel and shown
as histoplots (right panel). C, binding of HIV-1 gp120- and SEA-coated beads to the cells was measured using the fluorescent bead adhesion assay
as in B and shown as % binding. In addition to SEA-bio (see B), fluorescent beads coupled to an anti-LDN-monoclonal antibody (25) were used to
capture SEA (SEA-LDN). One representative experiment of three is shown. D, the binding of fluorescent beads coated with biotinylated SEA
(SEA-bio) was blocked by AZN-D2 (20 g/ml) and EGTA (5 mM). One representative experiment of three is shown.
FIG. 2. Binding of Lex coupled to biotinylated polyacrylamide
(Lex-PAA-bio) to K562 cells expressing L-SIGN or DC-SIGN. A,
cells were incubated with Lex-PAA-bio in adhesion buffer for 30 min at
37 °C. After incubation with goat-anti-mouse streptavidin Alexa
Fluor488, the binding was measured by FACScan analysis, and shown
as a histoplot. The white graphs represent control cells, the black
graphs show binding of the cells to Lex-PAA-bio. One representative
experiment of three is shown. B, binding of K562 cells expressing
L-SIGN or DC-SIGN to Lex-PAA-bio (indicated as Lex) was measured as
outlined in A but shown here as percent binding. Binding of Lex-PAA-
bio to DC-SIGN could be blocked by EGTA and the anti-L-SIGN/DC-
SIGN antibody AZN-D2. One representative experiment of three is
shown.
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tures of the whole C-type lectin family. sLex is bound to E- and
P-selectin with oxygen O-3 and O-4 of fucose interacting with the
calcium ion (33). Alternatively, fucose and several sialyl and sulfo-
Lex derivatives are bound to mannose-binding protein with O-2 and
O-3 of fucose involved in calcium coordination (34–36).
Four docking modes were tested in the present study for Lex
interaction with DC-SIGN, the two described above and two
additional ones, with an inversion of the fucose orientation (i.e.
inversion of O-4 and O-3 in the first binding mode and inver-
sion of O-2 and O-3 in the second one). Only the two binding
modes previously observed in C-type lectins yielded stable in-
teractions without steric or hydrophobic conflict (Fig. 4). Bind-
ing mode A, which corresponds to the interaction observed for
sLex in E- and P-selectin, is energetically favored, because it is
stabilized by five hydrogen bonds between the fucose and the
protein and an additional one between O-6 of galactose and an
acidic group (Fig. 5). This particular hydrogen bond is also
observed in selectins with a conserved glutamate residue (33).
The second binding mode (Fig. 4B), corresponding to sulfo and
sLex in mannose-binding protein mutants (35), only displays
four hydrogen bonds. Thus it is proposed that DC-SIGN and
L-SIGN bind fucosylated oligosaccharides with similar orien-
tations as found in the selectins (Fig. 4A).
Docking of Other Oligosaccharides in DC-SIGN—The ener-
gy-minimized structures of DC-SIGN in complex with Lex and
Lea trisaccharides and Ley and Leb tetrasaccharides have been
calculated. The six hydrogen bonds described above are con-
served in all of these complexes (Table II). In addition, hydro-
phobic contact can be predicted between galactose aliphatic
groups and the aromatic ring of the amino acid residue Phe313.
Val351 of DC-SIGN is close to the fucose binding site and makes
strong hydrophobic contact with CH at position 1 and 2 of
fucose. For Lex, the methyl group of GlcNAc is also involved in
this hydrophobic patch (Fig. 5A), whereas for Lea, the CH2 of
the hydroxymethyl group plays the same role albeit at slightly
longer distance (Fig. 5B). No additional contacts are observed
for Leb and Ley. This model is fully compatible with the ob-
served binding of DC-SIGN to all Lewis antigens. In addition,
sLex has been docked in the binding site of DC-SIGN with the
same conformation as observed in E- and P-selectin crystals
(33). In the latter structures, the acidic group of NeuAc closely
interacts with amino acid residue Tyr48 allowing for the occur-
rence of a strong hydrogen bond between the acidic group of
FIG. 3. Binding of different Lewis
antigens coupled to PAA-bio to K562
cells expressing L-SIGN, DC-SIGN, or
mutant forms of the lectins. A, amino
acid sequence alignment of part of the
CRDs of L-SIGN (AAK20998) and DC-
SIGN (AAK20997) is depicted. The CRD
sequences are very similar as is shown by
the black boxes. Mutations in the CRD of
L-SIGN have been introduced at position
Ser363 as indicated by an arrow. B, stable
K562 transfectants express similar levels
of L-SIGN, DC-SIGN and different mu-
tant forms of L-SIGN and DC-SIGN, as
determined by FACScan analysis using
monoclonal antibody AZN-D2. One repre-
sentative experiment of three is shown. C,
binding of different Lewis antigens cou-
pled to PAA-bio to K562 cells expressing
wild-type or mutant forms of L-SIGN and
DC-SIGN. Cells were incubated with the
PAA-bio-neoglycoconjugates in adhesion
buffer for 30 min at 37 °C. After incuba-
tion with goat-anti-mouse streptavidin-
Alexa Fluor 488, the binding was meas-
ured by FACScan analysis as described in
the legend to Fig. 2 and shown as percent
binding. One representative experiment
of three is shown.
TABLE I
Structures of Lewis glycan antigens
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NeuAc monosaccharide and the hydroxyl group of the Tyr.
However, in DC-SIGN the equivalent position is occupied by
Phe313. There is no favorable interaction between the acidic
group of NeuAc and the hydrophobic aromatic group of Phe313,
which may explain the lack of binding of DC-SIGN to sLex.
Docking of Oligosaccharides in L-SIGN—The hydrophilic
amino acids of the L-SIGN binding site are identical to the ones
in DC-SIGN, and the Lewis oligosaccharides can be docked
with establishing the same network of six hydrogen bonds
(Table II). The only difference is Ser363 that replaces Val351 in
DC-SIGN. The substitution of a Val by a Ser destroys the
hydrophobic wall that was adjacent to the fucose residue and
creates a hydrophilic pocket that is not favorable for the methyl
group of GlcNAc in Lex (Fig. 5C). This may explain the lack of
binding of L-SIGN to Lex. However, when Lea is docked, Ser363
can establish a hydrogen bond with the O-6 of GlcNAc thereby
restoring part of the contacts that are lost (Fig. 5D) resulting in
binding of Lea. Leb and Ley have been modeled and did not
present additional interactions compared with their corre-
sponding trisaccharides Lea and Lex, respectively (data not
shown). Although this model explains binding of L-SIGN to
Leb, the observed binding of L-SIGN to Ley is not supported by
the model proposed.
Docking of Oligosaccharides in Mutant Forms of L-SIGN and
DC-SIGN—When Val351 of DC-SIGN is substituted by a Gly
residue, the hydrophobic interaction with the fucose residue is
lost. Furthermore, the GlcNAc residue does not interact at all
with the protein surface in this mutant, neither for Lex nor for
Lea (Fig. 5, E and F). The loop that contains this Gly appears to
be stable in our calculations, but it could have greater mobility
in solution, which will be entropically unfavorable for the bind-
ing of oligosaccharides. The same observations are made for the
S363G mutant in L-SIGN (data not shown). These data are
compatible with the observed lack of binding of both the DC-
SIGN V351G and L-SIGN S363G mutant to all Lewis antigens.
By contrast, the L-SIGN S363V mutant displays the same
strong hydrophobic stabilization of the fucose and the methyl
(or hydroxymethyl group) of GlcNAc as is observed in DC-SIGN
(data not shown), which corresponds with the observed in-
crease in binding of this mutant to all Lewis antigens and
S. mansoni SEA.
DISCUSSION
L-SIGN and DC-SIGN contain a single CRD, which mediates
recognition of either self-glycoproteins or carbohydrate anti-
gens on pathogens (38, 39). The CRDs of L-SIGN and DC-SIGN
show a high amino acid sequence identity suggesting that their
carbohydrate recognition profiles may be similar. Recently we
have demonstrated that DC-SIGN binds to S. mansoni SEA
through recognition of Lex antigens (15). Here we show that
L-SIGN binds to a different subset of SEA than DC-SIGN and
does not bind Lex antigens. These data show, for the first time,
a clear difference in binding properties between L-SIGN and
DC-SIGN, which may have important consequences for their
functions. In S. mansoni infections, egg antigens and their
major glycan antigen Lex are able to cause a switch toward
Th2-mediated immune responses (40). Although direct evi-
dence is still lacking, we consider it possible that the interac-
tion between Lex and DC-SIGN may contribute to a shift in the
Th1/Th2 balance in favor of persistence of the pathogen. The
binding of L-SIGN to SEA suggests that also this C-type lectin
could play an important role in the recognition of S. mansoni
egg antigens. However, the specific antigens within SEA that
are involved in interaction with L-SIGN as well as the func-
tional relevance of this interaction need to be further
investigated.
Our previous studies (15) suggested that amino acid residue
Val351 in DC-SIGN may have a crucial role in binding the Lex
antigen. Here we show that the mutation of Val351 into Gly in
DC-SIGN not only abrogated binding of DC-SIGN to Lex but
also to Lea, Leb, and Ley glycan antigens. L-SIGN has Ser363 in
the position equivalent to Val351 of DC-SIGN. Remarkably,
although L-SIGN does not bind to Lex, it shows binding to other
Lewis antigens. Docking of the Lewis oligosaccharides into
molecular models of the CRDs of L-SIGN and DC-SIGN indi-
cated that the Lewis antigens most likely dock in a mode
similar to sLex in E-selectin (Fig. 4). Apart from being energet-
ically the most favorable mode, only this mode is in agreement
with the data demonstrating that DC-SIGN and L-SIGN do not
bind sLex. In the docking mode based on mannose-binding
protein-A, sialic acid does not make any additional contacts
compared with Lex, which would predict binding of DC-SIGN
and L-SIGN to both Lex and sLex and contradicts binding
studies.
From the proposed models it appears that Val351 in DC-
SIGN is close to the fucose binding site and makes a strong
hydrophobic contact with CH at position 1 and 2 of fucose. In
L-SIGN the presence of a Ser instead of a Val creates a hydro-
philic pocket that is not favorable for the methyl group of
GlcNAc in Lex but can establish a hydrogen bond with the O-6
of GlcNAc. This may explain the observed differences of L-
SIGN binding to Lex and Lea. However, changing L-SIGN
Ser363 into a Val not only allowed binding to Lex but also
increased binding to all Lewis antigens, showing that a Val
residue is favored for binding the fucose-containing oligosac-
charides in the CRD domain.
All binding assays in this study have been performed with
cells expressing the recombinant C-type lectins or their mutant
forms at the cell surface where they may be assembled into
FIG. 4. Two proposed binding
modes for Lex trisaccharide with DC-
SIGN. Ribbon presentation of the binding
modes of Lex trisaccharide to DC-SIGN.
The bound calcium ions in the structure
are represented as gray spheres. A, simi-
lar to the observed binding of sialyl-Lex in
E-selectin (33). B, similar to the observed
binding site of 3-sulfo-Lewis x in modified
mannose-binding protein-A (35). All
drawings were performed with the MOL-
SCRIPT program (37).
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tetramers and interact with glycan ligands presented in mul-
tivalent form (16). The models that show docking of Lex, Lea,
Leb, and sLex in the CRDs of DC-SIGN, L-SIGN, and their
mutant forms correspond very well to the observed results of
the binding assays. However, comparison of the docking of Ley
with Lex in L-SIGN did not reveal additional interactions that
would explain binding of Ley, but not Lex, by L-SIGN. It is
possible that either additional contacts between Ley and the
CRD of L-SIGN are introduced in the tetrameric form of L-
SIGN or that more than one CRD is involved in the binding of
the oligosaccharide, which may result in another binding mode
of Ley in L-SIGN than proposed from the model.
It is remarkable, that DC-SIGN and L-SIGN interact with
such different oligosaccharide ligands, i.e. high mannose-type
N-glycans and Lewis antigens using the same region in their
CRDs. Many of the amino acid residues that interact with the
mannose-type glycans, i.e. Phe313, Glu347, Asn349, Val351,
Glu354, and Asn365 in DC-SIGN, and their corresponding resi-
dues in L-SIGN (16) are proposed here to be also involved in
binding to the Lewis structures. Interestingly, these amino acid
residues clearly interact with different monosaccharides, and
the individual importance of each of these contacts in the
FIG. 5. Models of the interaction of DC-SIGN, L-SIGN, and DC-SIGN/V351G with Lex and Lea. Models of the interaction of DC-SIGN
with Lex (A) and Lea trisaccharides (B), L-SIGN with Lex (C) and Lea trisaccharides (D), and DC-SIGN (V351G) with Lex (E) and Lea trisaccharides
(F). The calcium ion is represented by a gray sphere. Only the amino acids interacting directly with the sugars have been displayed.
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binding pocket may vary depending on the glycan that is
bound. Recently it was shown that mutating Gly346 in DC-
SIGN abrogated gp120 binding but enhanced ICAM-2 and
ICAM-3 binding (41), whereas mutation of Val351 abrogates
binding to ICAM-3 and Lex but not to HIV-1 gp120 (15, 28).
Thus, DC-SIGN appears to bind in a distinct but overlapping
manner to gp120 when compared with ICAM-2, ICAM-3, and
Lex. Differential recognition of carbohydrate ligands by DC-
SIGN and L-SIGN will be crucially involved in the functional
consequences of these interactions, which may lead to either
immune activation or suppression. Detailed structural knowl-
edge of the molecular interactions of DC-SIGN and L-SIGN
with their carbohydrate ligands may be exploited to develop
strategies for immune intervention, such as HIV-1 dissemina-
tion by DC-SIGN or dendritic cell-induced immunity.
Acknowledgments—We thank Drs. F. A. Lewis (Biomedical Research
Institute, Rockville, MD), A. K. Nyame, and R. D. Cummings (Univer-
sity of Oklahoma Health Sciences Center, Oklahoma City, OK) for the
kind gift of crude S. mansoni SEA and the LDN-specific monoclonal
antibody SMLDN1.1, respectively.
REFERENCES
1. Geijtenbeek, T. B., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C.,
Adema, G. J., Van Kooyk, Y., and Figdor, C. G. (2000) Cell 100, 575–585
2. Geijtenbeek, T. B., Krooshoop, D. J., Bleijs, D. A., van Vliet, S. J., van Duijn-
hoven, G. C., Grabovsky, V., Alon, R., Figdor, C. G., and Van Kooyk, Y.
(2000) Nat. Immunol. 1, 353–357
3. Geijtenbeek, T. B., Kwon, D. S., Torensma, R., van Vliet, S. J., van Duijnhoven,
G. C., Middel, J., Cornelissen, I. L., Nottet, H. S., KewalRamani, V. N.,
Littman, D. R., Figdor, C. G., and Van Kooyk, Y. (2000) Cell 100, 587–597
4. Lozach, P. Y., Lortat-Jacob, H., de Lacroix de Lavalette, A., Staropoli, I.,
Foung, S., Amara, A., Houles, C., Fieschi, F., Schwartz, O., Virelizier, J. L.,
Arenzana-Seisdedos, F., and Altmeyer, R. (2003) J. Biol. Chem. 278,
20358–20366
5. Pohlmann, S., Zhang, J., Baribaud, F., Chen, Z., Leslie, G. J., Lin, G., Granelli-
Piperno, A., Doms, R. W., Rice, C. M., and McKeating, J. A. (2003) J. Virol.
77, 4070–4080
6. Alvarez, C. P., Lasala, F., Carrillo, J., Muniz, O., Corbi, A. L., and Delgado, R.
(2002) J. Virol. 76, 6841–6844
7. Halary, F., Amara, A., Lortat-Jacob, H., Messerle, M., Delaunay, T., Houles,
C., Fieschi, F., Arenzana-Seisdedos, F., Moreau, J. F., and Dechanet-Mer-
ville, J. (2002) Immunity 17, 653–664
8. Tassaneetrithep, B., Burgess, T. H., Granelli-Piperno, A., Trumpfheller, C.,
Finke, J., Sun, W., Eller, M. A., Pattanapanyasat, K., Sarasombath, S.,
Birx, D. L., Steinman, R. M., Schlesinger, S., and Marovich, M. A. (2003) J.
Exp. Med. 197, 823–829
9. Geijtenbeek, T. B., van Vliet, S. J., Koppel, E. A., Sanchez-Hernandez, M.,
Vandenbroucke-Grauls, C. M., Appelmelk, B., and Van Kooyk, Y. (2003) J.
Exp. Med. 197, 7–17
10. Maeda, N., Nigou, J., Herrmann, J. L., Jackson, M., Amara, A., Lagrange,
P. H., Puzo, G., Gicquel, B., and Neyrolles, O. (2003) J. Biol. Chem. 278,
5513–5516
11. Tailleux, L., Schwartz, O., Herrmann, J. L., Pivert, E., Jackson, M., Amara, A.,
Legres, L., Dreher, D., Nicod, L. P., Gluckman, J. C., Lagrange, P. H.,
Gicquel, B., and Neyrolles, O. (2003) J. Exp. Med. 197, 121–127
12. Colmenares, M., Puig-Kroger, A., Pello, O. M., Corbi, A. L., and Rivas, L. (2002)
J. Biol. Chem. 277, 36766–36769
13. Colmenares, M., Corbi, A. L., Turco, S. J., and Rivas, L. (2004) J. Immunol.
172, 1186–1190
14. Cambi, A., Gijzen, K., de Vries, J. M., Torensma, R., Joosten, B., Adema, G. J.,
Netea, M. G., Kullberg, B. J., Romani, L., and Figdor, C. G. (2003) Eur.
J. Immunol. 33, 532–538
15. Van Die, I., van Vliet, S. J., Nyame, A. K., Cummings, R. D., Bank, C. M.,
Appelmelk, B., Geijtenbeek, T. B., and Van Kooyk, Y. (2003) Glycobiology
13, 471–478
16. Mitchell, D. A., Fadden, A. J., and Drickamer, K. (2001) J. Biol. Chem. 276,
28939–28945
17. Feinberg, H., Mitchell, D. A., Drickamer, K., and Weis, W. I. (2001) Science
294, 2163–2166
18. Appelmelk, B. J., Van Die, I., van Vliet, S. J., Vandenbroucke-Grauls, C. M.,
Geijtenbeek, T. B., and Van Kooyk, Y. (2003) J. Immunol. 170, 1635–1639
19. Frison, N., Taylor, M. E., Soilleux, E., Bousser, M. T., Mayer, R., Monsigny, M.,
Drickamer, K., and Roche, A. C. (2003) J. Biol. Chem. 278, 23922
20. Pohlmann, S., Soilleux, E. J., Baribaud, F., Leslie, G. J., Morris, L. S., Trows-
dale, J., Lee, B., Coleman, N., and Doms, R. W. (2001) Proc. Natl. Acad. Sci.
U. S. A. 98, 2670–2675
21. Soilleux, E. J., Barten, R., and Trowsdale, J. (2000) J. Immunol. 165,
2937–2942
22. Bashirova, A. A., Geijtenbeek, T. B., van Duijnhoven, G. C., van Vliet, S. J.,
Eilering, J. B., Martin, M. P., Wu, L., Martin, T. D., Viebig, N., Knolle, P. A.,
KewalRamani, V. N., Van Kooyk, Y., and Carrington, M. (2001) J. Exp.
Med. 193, 671–67820
23. Engering, A., Van Vliet, S. J., Hebeda, K., Jackson, D. G., Prevo, R., Singh,
S. K., Geijtenbeek, T. B., van Krieken, H., Van Kooyk, Y., (2004) Am. J.
Pathol. 164, 1587–1595
24. Knolle, P. A., and Gerken, G. (2000) Immunol. Rev. 174, 21–34
25. Nyame, A. K., Leppanen, A. M., DeBose-Boyd, R., and Cummings, R. D. (1999)
Glycobiology 9, 1029–1035
26. Nyame, A. K., Lewis, F. A., Doughty, B. L., Correa-Oliveira, R., and Cum-
mings, R. D. (2003) Exp. Parasitol. 104, 1–13
27. Geijtenbeek, T. B., Van Kooyk, Y., van Vliet, S. J., Renes, M. H., Raymakers,
R. A., and Figdor, C. G. (1999) Blood 94, 754–764
28. Geijtenbeek, T. B., van Duijnhoven, G. C., van Vliet, S. J., Krieger, E., Vriend,
G., Figdor, C. G., and Van Kooyk, Y. (2002) J. Biol. Chem. 277,
11314–11320
29. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H.,
Shindyalov, I. N., and Bourne, P. E. (2000) Nucleic Acids Res. 28, 235–242
30. Clark, M., Cramer, R. D. I., and van den Opdenbosch, N. (1989) J. Comput.
Chem. 10, 982–1012
31. Imberty, A., Mikros, E., Koca, J., Mollicone, R., Oriol, R., and Pe´rez, S. (1995)
Glycoconj. J. 12, 331–349
32. Imberty, A., Bettler, E., Karababa, M., Mazeau, K., Petrova, P., and Pe´rez, S.
(1999) in Perspectives in Structural Biology (Vijayan, M., Yathindra, N., and
Kolaskar, A. S., eds), pp. 392–409, Indian Academy of Sciences and Uni-
versities Press, Hyderabad
33. Somers, W. S., Tang, J., Shaw, G. D., and Camphausen, R. T. (2000) Cell 103,
467–479
34. Ng, K. K., Drickamer, K., and Weis, W. I. (1996) J. Biol. Chem. 271, 663–674
35. Ng, K. K., and Weis, W. I. (1997) Biochemistry 36, 979–988
36. Ng, K. K., Kolatkar, A. R., Park-Snyder, S., Feinberg, H., Clark, D. A., Dricka-
mer, K., and Weis, W. I. (2002) J. Biol. Chem. 277, 16088–16095
37. Kraulis, P. (1991) J. Appl. Crystallogr. 24, 946–950
38. Geijtenbeek, T. B., Van Vliet, S. J., Engering, A., ’T Hart, B. A., Van Kooyk, Y.
(2004). Annu. Rev. Immunol. 22, 33–54
39. Van Die, I., Engering, A., and Van Kooyk, Y. (2004) Trends Glycosci. Glycotech-
nol. 16, 265–279
40. Okano, M., Satoskar, A. R., Nishizaki, K., and Harn, D. A. (2001) J. Immunol.
167, 442–450
41. Su, S. V., Hong, P., Baik, S., Negrete, O. A., Gurney, K. B., and Lee, B. (2004)
J. Biol. Chem. 279, 19122–19132
TABLE II
Hydrogen bonds involved in the binding of Lewis oligosaccharides by
DC-SIGN and L-SIGN
Sugar atom Donor/accept DC-SIGN L-SIGN
H-bonds predicted
for all Lewis
oligosaccharides
Fuc O-2 3 Glu354 OE-2 Glu366 OE-2
Fuc O-3 3 Glu354 OE-2 Glu366 OE-2
Fuc O-3 4 Asn365 ND-2 Asn377 ND-2
Fuc O-4 3 Glu347 OE-2 Glu359 OE-2
Fuc O-4 4 Asn349 ND-2 Asn361 ND-2
Gal O-6 3 Glu358 OE-1 Glu370 OE-1
H-bond predicted
for Lewis a
and Lewis b
oligosaccharides
GlcNAc O-6 4 Ser363 OG
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